Genomics company Illumina (NASDAQ:ILMN) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Illumina, Inc. (NASDAQ:ILMN) is one of the ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Illumina Inc (ILMN) reports robust EPS growth and strategic progress in multiomics, despite ongoing challenges in the Greater China market.

Illumina (ILMN) reported $1.08 billion in revenue for the ... The reported number represents a year-over-year change of +3.7%. Revenue- Sequencing- Consumables: $747 million compared to the $737.64 ...

Investing.com -- Illumina Inc (NASDAQ:ILMN) reported better-than-expected third-quarter results on Thursday, with earnings surpassing analyst estimates and the company raising its full-year outlook, ...

Illumina (($ILMN)) has held its Q3 earnings call. Read on for the main highlights of the call. Illumina’s recent earnings call painted a picture ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

Paul "PJ" Ortiz Jr. was climbing Mount Whitney in the Eastern Sierra mountains when he fell from a cliff in an infamous area ...